Logan Capital Management Inc. Has $15.26 Million Holdings in Pfizer Inc. $PFE

Key Points

• Logan Capital Management Inc. increased its investment in Pfizer Inc. by 14.5%, adding 76,174 shares to hold a total of 602,162 shares valued at $15,259,000.
• Recent analyst ratings show mixed sentiment towards Pfizer, with target prices ranging from $25.00 to $33.00, leading to a consensus rating of "Hold" and an average price target of $28.12.
• Pfizer reported earnings of $0.78 per share in its latest quarter, exceeding estimates, with revenues reaching $14.65 billion, an increase of 10.3% year-over-year.

Logan Capital Management Inc. grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 14.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 602,162 shares of the biopharmaceutical company's stock after buying an additional 76,174 shares during the quarter. Logan Capital Management Inc.'s holdings in Pfizer were worth $15,259,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the fourth quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE traded up $0.27 on Thursday, hitting $24.84. 36,770,116 shares of the stock were exchanged, compared to its average volume of 44,776,887. The company has a market capitalization of $141.23 billion, a PE ratio of 13.21, a P/E/G ratio of 0.88 and a beta of 0.55. The business's fifty day moving average is $24.83 and its 200 day moving average is $24.33. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PFE shares. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Finally, Jefferies Financial Group boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.